OUR PUBLICATIONS
2024
The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships
Fernow J, Olliver M, Couet W, Lagrange S, Lamers MH, Olesen OF, Orrling K, Pieren M, Sloan DJ, Vaquero JJ, Miles TJ, Karlén A.
Nat Rev Drug Discov. 2024 Sep 23.
2024
Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.
Byrne J, Gu L, Garcia-Leon A, Gaillard CM, Saini G, Alalwan D, Tomás-Cortázar J, Kenny G, Donohue S, Reynolds B, O'Gorman T, Landay A, Doran P, Stemler J, Koehler P, Cox RJ, Olesen OF, Lelievre JD, O'Broin C, Savinelli S, Feeney ER, O'Halloran JA, Cotter A, Horgan M, Kelly C, Sadlier C, de Barra E, Cornely OA, Gautier V, Mallon PW.
Front Immunol. 2024 Sep 17;15:1445653.
2024
Low Rates of Immunity among Medical Students and Residents in the Era of the Resurgence of Measles.
Ferrari C, Somma G, Caputi V, Treglia M, Pallocci M, Cenko F, Buonomo E, Carestia M, Di Giampaolo L, Olesen OF, Coppeta L.
Pathogens. 2024 Sep 11;13(9):784.
2024
How to develop a controlled human infection model for Clostridioides difficile.
Hensen ADO, Vehreschild MJGT, Gerding DN, Krut O, Chen W, Young VB, Tzipori S, Solbach P, Gibani MM, Chiu C, de Keersmaecker SCJ, Dasyam D, Morel S, Devaster JM, Corti N, Kuijper EJ, Roestenberg M, Smits WK.
Clin Microbiol Infect. 2024 Aug 29:S1198-743X(24)00425-7.
2024
How to develop a controlled human infection model for Clostridioides difficile.
Hensen ADO, Vehreschild MJGT, Gerding DN, Krut O, Chen W, Young VB, Tzipori S, Solbach P, Gibani MM, Chiu C, de Keersmaecker SCJ, Dasyam D, Morel S, Devaster JM, Corti N, Kuijper EJ, Roestenberg M, Smits WK.
Clin Microbiol Infect. 2024 Aug 29:S1198-743X(24)00425-7.
2024
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
Nkumama IN, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L, Murungi L, Tuju J, Fürle K, Rosenkranz M, Kimathi R, Njuguna P, Hamaluba M, Kapulu MC, Frank R. CHMI-SIKA study team; Osier FHA.
Immunity. 2024 Jun 11;57(6):1215-1224.e6.
2024
Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study.
Themistocleous S, Argyropoulos CD, Vogazianos P, Shiamakkides G, Noula E, Nearchou A, Yiallouris A, Filippou C, Stewart FA, Koniordou M, Kopsidas I, Askling HH, Vene S, Gagneux-Brunon A, Prellezo JB, Álvarez-Barco E, Salmanton-García J, Leckler J, Macken AJ, Davis RJ, Azzini AM, Armeftis C, Hellemans M, Di Marzo R, Luis C, Olesen OF, Valdenmaiier O, Jakobsen SF, Nauclér P, Launay O, Mallon P, Ochando J, van Damme P, Tacconelli E, Zaoutis T, Cornely OA, Pana ZD.
JMIR Public Health Surveill. 2024 Apr 4;10:e47241.
2024
Accelerating vaccine manufacturing development through model-based approaches: current advances and future opportunities
Ramin E, Cardillo AG, Liebers R, Schmölder J, von Lieres E, Van Molle W, Niebel B, Natalis L, Meln I, Perea-Vélez M, Clénet D, Jørgensen JB, Nilsson B, Bracewell DG, Gernaey KV.
Curr Opin Chem Eng. 2024;43:100998
2024
Ethical approval for controlled human infectious model clinical trial protocols - A workshop report.
Jamrozik E, Littler K, Meln I, Van Molle W, Morel S, Olesen OF, Rubbrecht M, Balasingam S, Neels P.
Biologicals. 2024 Feb;85:101748.
2024
Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.
Cavaleri M, Kaslow D, Boateng E, Chen WH, Chiu C, Choy RKM, Correa-Oliveira R, Durbin A, Egesa M, Gibani M, Kapulu M, Katindi M, Olotu A, Pongsuwan P, Simuyandi M, Speder B, Talaat KR, Weller C, Wills B, Baay M, Balasingam S, Olesen OF, Neels P.
Biologicals. 2024 Feb;85:101745.